OFFER DEADLINE30/07/2018 20:00 - Europe/Brussels
EU RESEARCH FRAMEWORK PROGRAMMEH2020 / Marie Skłodowska-Curie Actions
LOCATIONSpain, Barcelona (Hospitalet de Llobregat)
DEPARTMENTHereditary Cancer Program
The Hereditary Cancer Group of the Catalan Institute of Oncology (ICO, Barcelona, Spain) / Bellvitge Biomedical Research Institute (IDIBELL) is seeking for an excellent PostDoc candidate that is willing to apply for the Marie Curie Individual Fellowships 2018 call.
The position is to conduct research at the Catalan Institute of Oncology (ICO, Barcelona, Spain), a public comprehensive cancer center, affiliated to the Bellvitge Biomedical Research Institute (IDIBELL). Its approach to the disease is comprehensive, combining, all in one organization, prevention, care, specialized training and research. ICO has become a center of reference in Catalonia, both in healthcare quality and in research.
Hereditary Cancer Group
The overarching goal of our group is to gain insight into the molecular basis of hereditary cancer, to personalize risk assessment, as well as to individualize clinical management. Our multidisciplinary group facilitates fully comprehensive studies, data analysis, access to the patients and samples, and the translation of the obtained results to the clinics and genetic counseling.
Successful candidates will join a dynamic, young and well-equipped research group with strong interactions and multidisciplinary research. The group offers a stimulating research atmosphere and an environment in which collaboration and exchange of ideas and techniques is actively encouraged.
We are seeking for a candidate that will develop an ICO-CMRB project aimed at modelling the expressivity of cancer predisposition in Lynch syndrome through cell reprogramming of patient cells and 3-D cell culture methods.
IDIBELL is one of the most dynamic health research institutes in Spain with more than 800 researchers in the fields of basic, clinical and epidemiological research striving to attain significant improvements in human health. Research is structured into 3 thematic areas (cancer, neurosciences and translational medicine) with a total of 9 research programmes. IDIBELL has all of the facilities, infrastructure and equipment necessary to promote and support innovative, cutting edge research.
CMRB is a research institution co-founded in 2004 by the Autonomous Government of Catalonia and the Spanish Ministry of Health with the basic mission of conducting fundamental research of excellence to advance the clinical translation of strategies of regenerative medicine. One of the main research topics at CMRB is the generation of patient-specific iPS-based models of human diseases, and addressing the genetic complexity linked to increased risk or protection to suffering disease.
- Doctoral Degree in cellular molecular biology, genetics, biochemistry, biotechnology, medicine, or related discipline.
- For researchers in Europe: must not have spent or carried out the main activity (work, studies, etc.) in Spain for more than 12 months between 12th September 2015 and 12th September 2018.
- For researchers outside Europe: must not have spent or carried out the main activity (work, studies, etc.) in Spain for more than 36 months between 12th September 2013 and 12th September 2018.
- Additional skills and knowledge:
- English proficiency
- Good communication skills
- High motivation and ability to be involved in a multidisciplinary team
- Any participation in research projects, co-authorship in publications and mobility experience will be considered as a valuable asset.
- Experience in:
- Human genetics and molecular biology (including cancer biology)
- Cell engineering, CRISPR/Cas9 technology, cell reprogramming and 3-D cell cultures will be also valued.
To apply, please send a cover letter containing a statement of research interest and experience, a CV and names and contact information for three researchers that are familiar with you and with your work to Dr. Gabriel Capellá (email@example.com) and Marta Pineda (firstname.lastname@example.org) before 30th July 2018.